Crescent Biopharma to Present at September Investor Conferences

WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September:

• 2026 Cantor Global Healthcare Conference, fireside chat on Thursday, September 10, 2026 at 1:35 p.m. ET in New York.
  
  
• Morgan Stanley 24^th Annual Global Healthcare Conference, fireside chat on Monday, September 14, 2026 at 5:35 p.m. ET in New York.
  

A live webcast of each presentation will be available in the Investors section of the Company's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Contacts

Investors
Amy Reilly
Chief Communications Officer
[email protected]
617-465-0586

Media
Jenna Poist
Director, Corporate Communications
[email protected]
781-671-5019

You May Also Be Interested In

• Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
• Wellchange Holdings Company Limited Announces 1-for-5 Reverse Stock Split Effective September 8, 2026
• CN Reports August Grain Movement